Results 1 to 10 of about 935 (70)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Advanced Science, 2023
The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide
Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun   +14 more
doaj   +1 more source

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies

Frontiers in Oncology, 2021
The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy.
Hui Lu, Xiaoyan Zhao, Ziying Li, Yu Hu, Huafang Wang   +4 more
doaj   +1 more source

NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells

Frontiers in Immunology, 2022
Dominant inhibitory receptors for HLA class I (HLA-I) endow NK cells with high intrinsic responsiveness, a process termed licensing or education, but hinder their ability to kill HLA-I+ tumor cells. Cancer immunotherapy with adoptive transfer of NK cells
Xiaoxuan Zhuang, Eric O. Long
doaj   +1 more source

Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer

Frontiers in Pharmacology, 2020
Chimeric antigen receptor (CAR)-modified natural killer (NK) cell therapy represents a kind of promising anti-cancer treatment because CAR renders NK cells activation and recognition specificity toward tumor cells.
Shuo Yang, Shuo Yang, Bihui Cao, Guangyu Zhou, Guangyu Zhou, Lipeng Zhu, Lipeng Zhu, Lu Wang, Li Zhang, Hang Fai Kwok, Hang Fai Kwok, Zhenfeng Zhang, Qi Zhao, Qi Zhao   +13 more
doaj   +1 more source

Single VHH-directed BCMA CAR-NK cells for multiple myeloma

Experimental Hematology & Oncology, 2023
Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells.
Quan Ren, Yingling Zu, Hongchang Su, Qiumei Lu, Bin Xiang, Yanping Luo, Jishuai Zhang, Yongping Song   +7 more
doaj   +1 more source

ENHANCED ANTI-TUMOR ACTIVITY OF CD19.CAR-NK CELLS BY INCORPORATING IL-27

Hematology, Transfusion and Cell Therapy, 2023
Autologous T-cells expressing Chimeric Antigen Receptor (CAR) have shown great efficacy against hematologic malignancies, however, severe side effects limit their clinical use.
AFB Biggi, RN Silvestre, JTC Azevedo, MC Tirapelle, KCR Malmegrim, ML Figueiredo, DT Covas, V Picanço-Castro   +7 more
doaj   +1 more source

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma

Frontiers in Immunology, 2023
Head and neck squamous cell carcinoma (HNSCC) is a major challenge for current therapies. CAR-T cells have shown promising results in blood cancers, however, their effectiveness against solid tumors remains a hurdle. Recently, CD44v6-directed CAR-T cells
Ioana Sonya Ciulean, Joe Fischer, Andrea Quaiser, Christoph Bach, Hinrich Abken, Uta Sandy Tretbar, Stephan Fricke, Ulrike Koehl, Ulrike Koehl, Dominik Schmiedel, Dominik Schmiedel, Thomas Grunwald   +11 more
doaj   +1 more source

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Journal of Hematology & Oncology, 2020
Natural killer (NK) cells are a critical component of the innate immune system. Chimeric antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding antigens, creating major opportunities in the fight against cancer.
Ahmet Yilmaz, Hanwei Cui, Michael A. Caligiuri, Jianhua Yu   +3 more
doaj   +1 more source

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma

Journal of Immunology Research, 2017
The chimeric antigen receptor-modified immune effector cell (CAR-T and CAR-NK) therapies are newly developed adoptive treatments of cancers. However, their therapeutic efficacy against solid tumors is limited.
Qing Zhang, Kang Tian, Jinjing Xu, Haixu Zhang, Liantao Li, Qiang Fu, Dafei Chai, Huizhong Li, Junnian Zheng   +8 more
doaj   +1 more source

Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors

iScience, 2021
Summary: Despite the remarkable success of chimeric antigen receptor (CAR)-T cells against hematologic malignancies, severe off-tumor effects have constrained their use against solid tumors. Recently, CAR-engineered natural killer (NK) cells have emerged
Ana L. Portillo, Richard Hogg, Sophie M. Poznanski, Eduardo A. Rojas, Niamh J. Cashell, Joanne A. Hammill, Marianne V. Chew, Mira M. Shenouda, Tyrah M. Ritchie, Quynh T. Cao, Jeremy A. Hirota, Sukhbinder Dhesy-Thind, Jonathan L. Bramson, Ali A. Ashkar   +13 more
doaj   +1 more source